21036 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof; Hydrolases (3) acting on peptide bonds (3.4); Serine endopeptidases (3.4.21) Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
Methods and compositions related to long half-life coagulation complexes
#302Factor IX Polypeptides and Methods of Use Thereof
#303Glycopolysialylation of non-blood coagulation proteins
#304ALBUMIN FUSION PROTEINS
#305Method to achieve extended expression of DNA infused into liver
#306MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
#307Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
#308COAGULATION FACTOR VII POLYPEPTIDES
#309Chromatographic methods for purification of proteins from plasma
#310MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#311Stabilised Solid Compositions of Factor VII Polypeptides
#312Optimized liver-specific expression systems for FVIII and FIX
#313RECOMBINANT AAV VECTORS USEFUL FOR REDUCING IMMUNITY AGAINST TRANSGENE PRODUCTS
#314EXCIPIENTS FOR USE IN ADENO-ASSOCIATED VIRUS PHARMACEUTICAL FORMULATIONS AND PHARMACEUTICAL FORMULATIONS MADE THEREWITH
#315Systemic and topical application of platelet microparticles to treat bleeding in trauma patients
#316Optimised subcutaneous therapeutic agents
#317Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#318ADMINISTRATION OF PLANT EXPRESSED ORAL TOLERANCE AGENTS
#319Modified polynucleotides for the production of oncology-related proteins and peptides
#320Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#321Factor VII conjugates
#322Factor IX polypeptide mutant, its uses and method for its production
#323In vivo production of proteins
#324Methods for purifying FXa variant proteins
#325Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#326Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#327SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#328One component fibrin glue comprising zymogens
#329GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES
#330NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS
#331Lipid formulations for delivery of messenger RNA
#332Functions of 55 Newfound Proteins and Their Medicinal Application in the Treatment and Prevention of Disease
#333Delivery and formulation of engineered nucleic acids
#334Biodegradable lipids for delivery of nucleic acids
#335Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#336Lipid nanoparticle compositions and methods for MRNA delivery
#337Antidotes for factor Xa inhibitors and methods of using the same
#338AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR
#339METHOD OF MANUFACTURING PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION III AND NON-PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION IV
#340Liver-specific nucleic acid regulatory elements and methods and use thereof
#341Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#342Silicone free drug delivery devices
#343Lyophilized factor IX formulations
#344Recombinant AAV vectors useful for reducing immunity against transgene products
#345Lipids and lipid nanoparticle formulations for delivery of nucleic acids
#346Prohemostatic proteins for the treatment of bleeding
#347GLYCOPEGYLATED FACTOR IX
#348Humanized viral vectors and methods of use thereof
#349Stabilised Solid Compositions of Factor VII Polypeptides
#350COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION
#351SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#352COAGULATION FACTOR VII POLYPEPTIDES
#353Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#354Systems and methods for nucleic acid expression in vivo
#355MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE
#356COPOLYMERS OF FORMULA (I) AND USES
#357Tissue factor pathway inhibitor antibodies and uses thereof
#358Targeted coagulation factors and method of using the same
#359HALF-LIFE EXTENDED FACTOR FVIIA PROTEIN FOR PREVENTION AND TREATMENT OF BLEEDING AND DOSING REGIMENS THEREFOR
#360POLYMER FACTOR IX MOIETY CONJUGATES
#361Coagulation Factor IX Conjugates
#362MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
#363SODIUM CHLORIDE SOLUTION FOR DRUG RECONSTITUTION OR DILUTION
#364Serine Protease Primary Hemostatic Agent
#365Delivery methods and compositions for nuclease-mediated genome engineering
#366UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#367GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
#368Pharmaceutical composition with improved stability containing factor VII fusion protein
#369Short-acting factor VII polypeptides
#370Modified polynucleotides for the production of secreted proteins
#371Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
#372COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE
#373Compositions and methods for modulating hemostasis
#374Blood coagulation protein conjugates
#375Glycopegylated Factor IX
#376Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#377Antidotes for factor Xa inhibitors and methods of using the same
#378FUSION PROTEINS COMPRISING FACTOR IX FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF
#379Factor IX polypeptides and methods of use thereof
#380Population pharmacokinetics tools and uses thereof
#381Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#382ENGINEERED GLYCOPROTEINS AND USES THEREOF
#383Methods of using a fixed dose of a clotting factor
#384Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
#385STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE
#386Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
#387Protein Formulations Containing Amino Acids
#388Factor VII composition
#389Coagulation Factor-Targeting to TLT-1 on Activated Platelets
#390Factor IX polypeptides and methods of use thereof
#391Stabilizing agent for pharmaceutical proteins
#392Long-acting coagulation factors and methods of producing same
#393Factor IX polypeptides and methods of use thereof
#394LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE
#395Compositions and Methods for Increasing the Half-Life of Factor XA
#396Stabilised Solid Compositions of Factor VII Polypeptides
#397MATERIAL TO PREVENT POST SURGICAL INFECTION
#398Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#399Modified factor IX polypeptides and uses thereof
#400Modified polynucleotides for the production of proteins associated with human disease
#401MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER
#402Methods and compositions for detecting coagulation inhibitors
#403Glycopegylated Factor IX
#404SINGLE CHAIN FC FUSION PROTEINS
#405Factor IX polypeptides and methods of use thereof
#406Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#407Modified polynucleotides for the production of proteins
#408LOW VISCOSITY COMPOSITIONS COMPRISING A PEGYLATED GLA-DOMAIN CONTAINING PROTEIN
#409Factor X mutants
#410Polymers for delivery of factor VIII and/or factor IX
#411Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life
#412FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND METHOD FOR ITS PRODUCTION
#413FACTOR IX VARIANTS AND METHODS OF USE THEREFOR
#414Modified Glycoproteins Having Circulating Half-Lives
#415BLOOD COAGULATION PROTEIN CONJUGATES
#416Modified polynucleotides for the production of nuclear proteins
#417METHODS FOR TREATING BLEEDING DISORDERS USING A PLATELET SUBPOPULATION
#418Human coagulation factor light chain protein and use of the same
#419Stabilised Compositions of Factor VII Polypeptides
#420SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#421Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#422Long-acting coagulation factors and methods of producing same
#423METHODS AND COMPOSITIONS FOR ATTENUATING GENE EDITING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
#424METHODS AND COMPOSITIONS FOR ATTENUATING GENE THERAPY ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
#425Production of fully processed and functional factor X in a furin-secreting mammalian expression system
#426Therapeutic agents comprising a GLP-2 peptide and elastin-like peptides
#427Monoclonal antibodies against antithrombin β
#428MODULATION OF FACTOR XA INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
#429Antidotes for factor XA inhibitors and methods of using the same
#430Factor IX polypeptide formulations
#431In vivo production of proteins
#432Modified polynucleotides for the production of secreted proteins
#433A METHOD OF VIRUS INACTIVATION IN COMPOSITION COMPRISING FACTOR VII
#434Chimeric clotting factors
#435INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
#436Extracellular histones as biomarkers for prognosis and molecular targets for therapy
#437GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS
#438Stabilised Solid Compositions of Factor VII Polypeptides
#439COMPOSITIONS AND METHODS FOR COUNTERACTING FACTOR XA INHIBITION
#440Use of antidotes to coagulation inhibitors indicated in the prevention or treatment of thromboembolic pathologies
#441FACTOR IX VARIANTS
#442THROMBIN-FREE BIOLOGICAL ADHESIVE AND USE THEREOF AS A MEDICAMENT
#443METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#444Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
#445LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE
#446FACTOR VII CONJUGATES
#447GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES
#448COMPOSITIONS OF HUMAN PROTHROMBIN AND ACTIVATED FACTOR X FOR IMPROVING HEMOSTASIS IN THE TREATMENT OF BLEEDING DISORDERS
#449Modified polynucleotides for the production of nuclear proteins
#450Factor VII Conjugates
#451Coagulation Factor IX Conjugates
#452Factor VII composition
#453FVII polypeptide variants exhibiting altered interaction with endothelial protein C receptor (EPCR) and methods of use thereof for modulating hemostasis
#454SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#455Albumin binding probes and drug conjugates thereof
#456Procoagulant compounds
#457FXa variant compositions
#458Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#459Therapeutic agent for epithelial and endothelial injury
#460One component fibrin glue comprising zymogens
#461Modified polynucleotides for the production of cosmetic proteins and peptides
#462Lipid formulations
#463Conjugates of biologically active molecules to functionalized polymers
#464Lipid formulations for delivery of messenger RNA
#465Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#466Glycopegylated Factor IX
#467PRODRUGS CONTAINING ALBUMIN BINDING PROBE
#468OPTIMISED SUBCUTANEOUS THERAPEUTIC AGENTS
#469Therapeutic agents comprising fusions of growth hormone and elastic peptides
#470Modified polynucleotides for the production of proteins
#471Antidotes for factor Xa inhibitors and methods of using the same
#472Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
#473UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#474MEDICINAL PRODUCTS FOR THE TREATMENT OF BLOOD COAGULATION DISORDERS
#475Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues
#476Internally functionalized graphene substrates
#477Delivery and formulation of engineered nucleic acids
#478Factor XII inhibitors for the treatment of neurological inflammatory disorders
#479C-terminally tethered amino acids and their fibrinolytic therapeutic uses
#480Short-acting factor VII polypeptides
#481Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#482Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
#483Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
#484Extracellular histones as biomarkers for prognosis and molecular targets for therapy
#485Chimeric factor VII molecules
#486Pulmonary delivery of mRNA
#487MRNA therapy for Fabry disease
#488Methods for treating bleeding disorders using a platelet subpopulation
#489Monoclonal antibodies against antithrombin β
#490MONOCLONAL ANTIBODIES AGAINST ANTITHROMBIN BETA
#491Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof
#492METHODS OF USING ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING BLEEDING DISORDERS
#493Modified factor X polypeptides and uses thereof
#494Targeted coagulation factors and method of using the same
#495Stabilizing agent for pharmaceutical proteins
#496PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VII ENCAPSULATED IN MICELLES
#497Therapeutic agents comprising fusions of insulin and elastic peptides
#498Stabilised Solid Compositions of Factor VII Polypeptides
#499ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS
#500Protein formulations containing amino acids
#501Stabilised Compositions of Factor VII Polypeptides
#502Compositions and methods for modulating hemostasis
#503Modified vitamin K-dependent polypeptides
#504Antidotes for factor Xa inhibitors and methods of using the same
#505Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
#506Procoagulant molecular decoy for treating hemophilia A or B with or without inhibitor
#507Antidotes for factor XA inhibitors and methods of using the same
#508AAV8 vector with enhanced functional activity and methods of use thereof
#509Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#510Modified factor X polypeptides and uses thereof
#511Treatment with factor ix-albumin fusion protein
#512Treatment with factor VII-albumin fusion protein
#513Cell migration regulator
#514Formulations of Factor VIIa inhibitors and utility
#515Long-acting coagulation factors and methods of producing same
#516Factor II and fibrinogen for treatment of haemostatic disorders
#517Albumin Fusion Proteins
#518Factor IX polypeptides and methods of use thereof
#519Modified factor IX polypeptides and uses thereof
#520Factor IX polypeptides and methods of use thereof
#521STABLE COMPOSITIONS OF FACTOR IX
#522THROMBIN-FREE BIOLOGICAL ADHESIVE AND USE THEREOF AS A MEDICAMENT
#523Conjugated blood coagulation factor VIIa
#524Antidotes for factor Xa inhibitors and methods of using the same
#525Therapeutic agents comprising insulin and elastin-like peptides
#526Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides
#527Methods of treating diabetes using therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptides
#528Analgesic and anti-inflammatory composition
#529Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#530Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
#531SUSTAINED PREPARATION OF FACTOR IX
#532Stabilised solid compositions of factor VII polypeptides
#533Administration of plant expressed oral tolerance agents
#534THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES
#535Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
#536STABLE SOLUTION
#537METHODS AND COMPOSITIONS TO TREAT HEMORRHAGIC CONDITIONS OF THE BRAIN
#538Modified factor IX polypeptides and uses thereof
#539COMPOSITIONS FOR ORAL GENE THERAPY AND METHODS OF USING SAME
#540Antidotes for factor Xa inhibitors and methods of using the same
#541ALBUMIN FUSION PROTEINS
#542Engineered nucleic acids encoding a modified erythropoietin and their expression
#543PLASMA PROTEIN EFFECTIVE FOR SUPPRESSING COUGH
#544Glycopegylation methods and proteins/peptides produced by the methods
#545Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
#546Lipid formulation
#547Method for forming III-V semiconductor structures including aluminum-silicon nitride passivation
#548ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS
#549Albumin fusion proteins
#550Albumin Fusion Proteins
#551PRODRUGS CONTAINING ALBUMIN BINDING PROBE
#552Methods for treating bleeding disorders using sulfated polysaccharides
#553PROTEIN CONJUGATE HAVING AN ENDOPEPTIDASE- CLEAVABLE BIOPROTECTIVE MOIETY
#554COMPOSITIONS AND METHODS FOR TREATING PLASMA PROTEIN DEFICIENCY DISORDERS
#555Factor VII composition
#556Modified Blood Factors Comprising a Low Degree of Water Soluble Polymer
#557CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE
#558METHODS OF MANAGING THE BLOOD COAGULATION AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO
#559Method and means for producing tissues and tissues obtained
#560Logic-Driven Layout Verification
#561Liquid composition of factor VII polypeptides
#562Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
#563Logic-driven layout verification
#564Thrombin-free composition containing freeze-dried, virally inactivated FXIa and serpins and/or kininogen
#565Method for treating a patient
#566Albumin Fusion Proteins
#567Methods and Compositions for use in Gene Therapy for Treatment of Hemophilia
#568Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
#569Factor IX polypeptide mutant, its uses and a method for its production
#570Methods for treating bleeding disorders using sulfated polysaccharides
#571Liver-specific nucleic acid regulatory elements and methods and use thereof
#572Clotting factor-fc chimeric proteins to treat hemophilia
#573MODIFIED HUMAN FACTOR VII/VIIA AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
#574Method for detecting adeno-associated virus
#575Methods and compositions to treat hemorrhagic conditions of the brain
#576Nanoparticles for protein drug delivery
#577Compositions of Less Immunogenic and Long-Circulating Protein-Lipid Complexes
#578Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
#579LOW VISCOSITY COMPOSITIONS COMPRISING A PEGYLATED GLA-DOMAIN CONTAINING PROTEIN
#580Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI
#581Modulation of Adenoviral Tropism
#582FORMULATIONS OF PEG-FUNCTIONALISED SERINE PROTEASES WITH HIGH CONCENTRATIONS OF AN AROMATIC PRESERVATIVE
#583Composition and method for the repair and regeneration of cartilage and other tissues
#584Targeted Coagulation Factors and Method of Using the Same
#585FACTOR VIIA-POLYSIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE
#586Factor VII Polypeptides for Preventing Formation of Inhibitors in Subjects with Haemophilia
#587Combination therapy with a compound acting as a platelet ADP receptor inhibitor
#588Blood coagulation protein conjugates
#589Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
#590Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
#591Blood coagulation factor inhibitors
#592FVII OR FVIIA VARIANTS
#593One pot desialylation and glycopegylation of therapeutic peptides
#594Glycopegylated factor IX
#595Chimeric factor VII molecules
#596Lipid formulation
#597STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE
#598Modified vitamin K-dependent polypeptides
#599Stabilisation of Liquid-Formulated Factor VII(A) Polypeptides by Aldehyde-Containing Compounds
#600High concentration factor VII polypeptide formulations comprising an aromatic preservative and an antioxidant